The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap

A Closer Look at Antibodies in RA: How Anti-Citrullinated Protein Antibodies, Anti-Modified Protein Autoantibodies & Rheumatoid Factor Activity Overlap

December 17, 2020 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—Recent research findings suggest rheumatologists need to take a closer look at two gold standard autoantibodies used to diagnose seropositive rheumatoid arthritis (RA)—rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP), according to Caroline Grönwall, PhD, associate professor in the Division of Rheumatology at Karolinska Institute, Stockholm, and Miriam Shelef, MD, PhD, associate professor in the Division of Rheumatology at the University of Wisconsin-Madison School of Medicine and Public Health, where she runs a research program.

You Might Also Like
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • A Close Look at Antibodies in RA
Also By This Author
  • ACR Practice Experts Can Answer Challenging Business Questions

Rheumatoid factor is a measure of antibodies against IgG. Anti-CCP is a surrogate for anti-citrullinated protein antibodies. These antibodies have traditionally been used to measure autoantibody status for early identification of seropositive RA.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

During the ACR Convergence session Antibodies in RA: Beyond Citrullination & Back to Rheumatoid Factor, these investigators discussed new evidence in their respective study areas that could influence how RA antibodies are assessed and used for diagnostics and understanding preclinical RA development. 

Present & New Roles for Autoreactivity to Citrullination
Dr. Grönwall leads a research team investigating how autoantibodies and autoreactive B cells contribute to the pathogenesis of human diseases like RA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

RA is associated with antibodies to anti-citrullinated proteins, commonly known as ACPAs. Citrullination happens when a post-translational modification of the amino acid arginine to citrulline occurs. Dr. Grönwall began by discussing what is known about this autoreactivity.

ACPAs are routinely detected with a cyclic citrullinated peptide (CCP) test. Yet, peptide screenings show that each patient may have different ACPA-fine specificities (i.e., may have a particular pattern of ACPA targeting different citrullinated antigens). A range of autoantigens has been investigated—some of the favorites include citrullinated fibrinogen, vimentin, alpha-enolase, histones and collagen type II. Dr. Grönwall showed what autoreactivity profiles look like in a cohort of RA patients to demonstrate that RA patients can have their own unique profiles of ACPA-fine specificities, but pointed out glycines in many of these peptides, either in the plus one position compared with citrulline or in the minus one position.

Besides using serology and polyclonal antibodies to address autoreactivity, the Karolinska Institute research team has in collaborative efforts, used an approach working with monoclonal antibodies from single B cells in RA patients from a variety of sources, including synovial fluid, lung tissue, gingiva tissue and bone marrow, and identified approximately 30 different monoclonal ACPAs that are CCP-reactive. Methods are described in an online protocol and some monoclonal antibodies [mAbs] have been published by Steen et al. and Titcombe et al.; others are in progress.2,3,4 These monoclonal antibodies each bind to several different citrullinated peptides and are multi-reactive.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: ACR Convergence 2020, anti-cyclic citrullinated peptide (anti-CCP), meeting reports, Rheumatoid Arthritis (RA), Rheumatoid Factor

You Might Also Like:
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)
  • ACR/ARHP Annual Meeting 2012: Can Studying Anticitrullinated Protein Antibodies Put Us on Track to Stop RA?
  • A Close Look at Antibodies in RA
  • ACR/ARHP Annual Meeting 2012: Genes Not the Only Factor in Susceptibility to Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)